These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12904142)

  • 41. Management of statin-intolerant high-risk patients.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2010 Sep; 8(5):632-7. PubMed ID: 20507273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statins and solid organ transplantation.
    Gazi IF; Liberopoulos EN; Athyros VG; Elisaf M; Mikhailidis DP
    Curr Pharm Des; 2006; 12(36):4771-83. PubMed ID: 17168777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there value in liver function test and creatine phosphokinase monitoring with statin use?
    Sniderman AD
    Am J Cardiol; 2004 Nov; 94(9A):30F-34F. PubMed ID: 15519289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care.
    Stein EA
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S36-9; discussion S45-7. PubMed ID: 11855701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of fluvastatin in cardiovascular risk management.
    McDonald KJ; Jardine AG
    Expert Opin Pharmacother; 2008 Jun; 9(8):1407-14. PubMed ID: 18473714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of hypercholesterolemia with statins].
    Erikssen J; Madsen S
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3216-20. PubMed ID: 9411860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study.
    Einarson TR; Metge CJ; Iskedjian M; Mukherjee J
    Clin Ther; 2002 Dec; 24(12):2126-36. PubMed ID: 12581550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drugs for the treatment of hypercholesterolaemia.
    Iglesias P; Díez JJ
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1777-89. PubMed ID: 14585054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atorvastatin.
    Wierzbicki AS
    Expert Opin Pharmacother; 2001 May; 2(5):819-30. PubMed ID: 11336625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
    Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM
    Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological actions of statins: a critical appraisal in the management of cancer.
    Gazzerro P; Proto MC; Gangemi G; Malfitano AM; Ciaglia E; Pisanti S; Santoro A; Laezza C; Bifulco M
    Pharmacol Rev; 2012 Jan; 64(1):102-46. PubMed ID: 22106090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The power of statins: aggressive lipid lowering.
    Jones PH
    Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
    Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Specific considerations on the prescription and therapeutic interchange of statins].
    García-Sabina A; Gulín-Dávila J; Sempere-Serrano P; González-Juanatey C; Martínez-Pacheco R
    Farm Hosp; 2012; 36(2):97-108. PubMed ID: 21820929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A general assessment of the safety of HMG CoA reductase inhibitors (statins).
    Black DM
    Curr Atheroscler Rep; 2002 Jan; 4(1):34-41. PubMed ID: 11772420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.